10-Q: Stereotaxis Reports Q2 2024 Results and Completes Acquisition of Access Point Technologies

Stereotaxis' Q2 2024 results show a decrease in revenue compared to the same period last year, alongside the completion of the acquisition of Access Point Technologies.

Summary

• Stereotaxis reported a decrease in revenue for the three and six months ended June 30, 2024, compared to the same periods in 2023.
• Total revenue for the three months ended June 30, 2024, was $4.5 million, a 43% decrease from $7.9 million in 2023.
• Revenue from systems sales decreased significantly to $0.2 million, down from $3.3 million in the same quarter of the previous year.
• Disposable, service, and accessories revenue also saw a slight decrease to $4.3 million, compared to $4.6 million in 2023.
• For the six months ended June 30, 2024, total revenue was $11.4 million, a 21% decrease from $14.4 million in 2023.
• The company's gross margin increased to 74% for the three months ended June 30, 2024, from 53% in 2023, primarily due to changes in product mix.
• Operating loss for the three months ended June 30, 2024, was $6.021 million, compared to $5.277 million in 2023.
• Net loss attributable to common stockholders was $6.158 million for the three months ended June 30, 2024, compared to $5.292 million in 2023.
• The company completed the acquisition of Access Point Technologies EP, Inc. on July 31, 2024, issuing 1,486,620 shares of common stock as upfront payment.
• Additional contingent payments in common stock are tied to future revenue and regulatory milestones through September 30, 2029.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While the acquisition is a positive strategic move, the financial results show a significant decline in revenue and increased losses. The ongoing risks and uncertainties also contribute to a negative sentiment.

Positives

• Gross margin increased to 74% for the three months ended June 30, 2024, from 53% for the three months ended June 30, 2023, primarily due to changes in product mix.
• The acquisition of Access Point Technologies is expected to enhance Stereotaxis' catheter development and manufacturing capabilities.

Negatives

• Total revenue decreased by 43% in Q2 2024 compared to Q2 2023.
• System revenue decreased significantly from $3.3 million to $0.2 million in Q2 2024.
• The company experienced an operating loss of $6.021 million for the three months ended June 30, 2024.
• Net loss attributable to common stockholders was $6.158 million for the three months ended June 30, 2024.

Risks

• The company continues to experience supply chain disruptions, shortages, and inflationary pressures.
• Economic pressures on hospital customers may lead to delays or cancellations of purchase orders.
• Disruptions to capital markets could negatively impact the company's ability to raise capital.
• Resurgences of the COVID-19 pandemic may negatively affect demand for systems and disposable products.

Future Outlook

The company anticipates periodic disruptions to manufacturing operations, supply chains, procedure volumes, service activities, and capital system orders and placements due to ongoing pandemic-related issues. The acquisition of Access Point Technologies is expected to advance the treatment of complex arrhythmias and the broad adoption of robotics within endovascular surgery.

Industry Context

The company operates in the multi-billion-dollar medical device market for cardiac ablation, which is expected to see substantial long-term growth. The acquisition of Access Point Technologies is a strategic move to expand the company's capabilities in this market.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• However, the company's focus on robotic magnetic navigation and its expansion into other endovascular indications aligns with broader trends in the medical device industry towards minimally invasive and robotic procedures.
• The acquisition of Access Point Technologies is a strategic move to enhance the company's competitive position in the cardiac ablation market.

Legal Proceedings

• In February 2024, a vendor filed financing statements under the Uniform Commercial Code (UCC) on underlying inventory for approximately $0.6 million, which the company is contesting.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and increased losses.
• Employees may be affected by the integration of Access Point Technologies.
• Customers may benefit from the expanded product offerings and capabilities.
• Suppliers may be impacted by changes in the company's supply chain.

Next Steps

• The company will focus on integrating Access Point Technologies into its business.
• The company will pursue regulatory approvals for the Stereotaxis MAGiC catheter in various global geographies.
• The company will continue to monitor and address supply chain disruptions and economic pressures.

Key Dates

Keywords

Stereotaxis, Access Point Technologies, robotic magnetic navigation, cardiac ablation, electrophysiology, medical devices, revenue, acquisition, financial results, catheters